Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks

2 Jan 2019

Abstract excerpt

Mutations in the ATM tumor suppressor gene confer hypersensitivity to DNA-damaging chemotherapeutic agents. To explore genetic resistance mechanisms, we performed genome-wide CRISPR-Cas9 screens in cells treated with the DNA topoisomerase I inhibitor topotecan. Thus, we here establish that inactivating terminal components of the non-homologous end-joining (NHEJ) machinery or of the BRCA1-A complex specifically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30622252
DOI: 10.1038/s41467-018-07729-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forksPMID 30622252Read ↗

ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forksSemantic proximity Read ↗

Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage responseSemantic proximity Read ↗

Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer’s Achilles’ HeelSemantic proximity Read ↗

CRISPR screens guide the way for PARP and ATR inhibitor biomarker discoverySemantic proximity Read ↗

Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA DamageSemantic proximity Read ↗

Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA DamageSemantic proximity Read ↗

Reversing regulatory safeguards: Targeting the ATR pathway to overcome PARP inhibitor resistanceSemantic proximity Read ↗

ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma.Semantic proximity Read ↗

PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7.Semantic proximity Read ↗

Dual genome-wide CRISPR knockout and CRISPR activation screens identify common mechanisms that regulate the resistance to multiple ATR inhibitorsSemantic proximity Read ↗

PARP inhibitor synthetic lethality reveals homologous recombination sub-pathway architectureSemantic proximity Read ↗

Resistance to DNA repair inhibitors in cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.